Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Goodwill (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Goodwill for 16 consecutive years, with $8.1 million as the latest value for Q4 2025.

  • Quarterly Goodwill rose 13.04% to $8.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.1 million through Dec 2025, up 13.04% year-over-year, with the annual reading at $8.1 million for FY2025, 13.04% up from the prior year.
  • Goodwill for Q4 2025 was $8.1 million at Anika Therapeutics, roughly flat from $8.1 million in the prior quarter.
  • The five-year high for Goodwill was $8.1 million in Q2 2021, with the low at $6.7 million in Q3 2022.
  • Average Goodwill over 5 years is $7.6 million, with a median of $7.5 million recorded in 2023.
  • The sharpest move saw Goodwill plummeted 76.2% in 2021, then grew 13.04% in 2025.
  • Over 5 years, Goodwill stood at $7.8 million in 2021, then dropped by 5.68% to $7.3 million in 2022, then rose by 3.16% to $7.6 million in 2023, then fell by 5.89% to $7.1 million in 2024, then grew by 13.04% to $8.1 million in 2025.
  • According to Business Quant data, Goodwill over the past three periods came in at $8.1 million, $8.1 million, and $8.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.